Zimmer Biomet Holdings (XSWX:ZBH) 5-Year EBITDA Growth Rate : 8.70% (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Zimmer Biomet Holdings 5-Year EBITDA Growth Rate?

Zimmer Biomet Holdings's EBITDA per Share for the three months ended in Dec. 2023 was CHF2.39.

During the past 12 months, Zimmer Biomet Holdings's average EBITDA Per Share Growth Rate was 49.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 29.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 8.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Zimmer Biomet Holdings was 43.60% per year. The lowest was -18.90% per year. And the median was 5.90% per year.

Competitive Comparison of Zimmer Biomet Holdings's 5-Year EBITDA Growth Rate

For the Medical Devices subindustry, Zimmer Biomet Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zimmer Biomet Holdings's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's 5-Year EBITDA Growth Rate falls into.

Zimmer Biomet Holdings 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Zimmer Biomet Holdings (XSWX:ZBH) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Zimmer Biomet Holdings 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Zimmer Biomet Holdings (XSWX:ZBH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (XSWX:ZBH) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ZBH:USA ZIM:Germany ZBH:Austria

Address

345 East Main Street, Warsaw, IN, USA, 46580

Website

https://www.zimmerbiomet.com

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.